Articles On Global Health (ASX:GLH)

Highlights   MDGH gains FDA approval for moxidectin to treat river blindness.   Ghana becomes the first river blindness-endemic country to approve moxidectin.   MDGH’s cost-plus pricing ensures affordable treatment for underserved pop...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Amplia CEO Dr Chris Burns and long-time scientific collaborator Professor Andrew Wilks have been awarded the 2024 Prime Minister’s Prize for Innovation The scientists were recognised for their breakthrough in developing momelotinib, a drug...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ — BioCina Pty Ltd., a global en...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Birth rates decline as people choose careers and pets Global pet industry is benefitting from this, to grow significantly by 2030 Ethical investing could thrive in sustainable pet product demand   The conversation around motherhood is evo...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

The S&P/ASX 200 Information Technology sector rose ~8% in August, despite a volatile month for global markets Global X said the Nasdaq had mixed performance driven by a combination of positive and negative factors  Wisetech Global rose...

S&P/ASX 200 recovers from heavy volatility early in the month to finish up 0.47% in August S&P Dow Jones Indices said mid-caps led the gains putting them ahead of large and small caps YTD Larvotto Resources rose on the back of Chin...

THC gummies are becoming popular for their convenience and effects Bioxyne has produced Australia’s first GMP-certified cannabis gummies Bioxyne is expanding production to meet rising demand   Functional foods are growing in popularity as...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

ASX smacked after Wall Street sell-off sparked a red day around the world. ALL sectors lower on Friday. Yep… all 11 of them. Small caps led by Spacetalk and Alto Metals   The local benchmark index is wallowing back under 8,000 points,...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX 200 ends 0.5pc lower after a difficult start to the week Energy Sector the worst of some poor to middling performances Small caps led by AuMake on news of a new deal in China   Last week’s record highs seem a distant memory for the...

Materials, Energy and Infotech dominate a sluggish day on Wednesday Booktopia collapses with a grim outlook for a final chapter ahead Some standout performances among the small caps, but who won?   The ASX 200 benchmark struggled to make...

Island Pharmaceuticals inks deal to develop a treatment for potentially deadly viruses like Ebola Amplia recruits key 26th patient in Phase 2a trial of new treatment for advanced pancreatic cancer  Melodiol Global Health records unaudited...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

S&P/ASX 200 rose 1% in June with large caps leading gains with mid, small and emerging companies lagging S&P/ASX 200 financials and consumer staples were the top performers in June with materials the biggest laggard Urea fertiliser...

Choppy day leaves the ASX 200 benchmark below zero, down -0.2pc Energy surges on news of a coal fire in Queensland, because that’s good for business everywhere else Small Caps winners’ list dominated by a $12 million boat sale by Wellard,...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Two independent appraisals value land and building owned by Melodiol’s Canadian subsidiary Mernova at between $10.4 – $12 million Appraisals follow strong revenue progress at Melodiol, with $21.6m in revenue delivered for FY23 ME1 inks de...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Mernova finalises additional product development activities across edibles, vapes and dabbers Agreements made with contract growers to supplement existing cannabis capacity given strong demand Q2 FY24 purchase orders of $1.56m to date, hi...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX losses accelerate after sluggish retail sector updates  Baby Bunting, Temple & Webster, JB Hi-fi all under pressure on soft sales Alliance Nickel soars on fat federal grant   After opening modestly higher this morning, the ASX qui...

Melodiol’s Canadian subsidiary Mernova continues to make strong progress Mernova launching additional products across various Canadian provinces Mernova has received purchase orders of $1.3 million in strong start to Q2 FY24    Special Re...

Neuren Pharma’s Q1 DAYBUE sales disappoint 4DMedical’s CT LVAS technology gets reimbursement in US Melodiol’s Canadian subsidiary, Mernova, continues to make strong progress   Neuren’s Q1 disappoints Neuren Pharma (ASX:NEU) slumped by ove...

  ASX to dip slightly at the open after a modest run on Wall Street Shopify, Airbnb and Uber took a dive overnight after earnings release What’s been moving the gold price?   Aussie shares are poised to open modestly lower on Thursday,...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Melodiol Global Health Q1 FY24 unaudited revenue of $4.4m marks a 91% increase on pcp Company remains focused on reducing operating costs, while pursuing high growth revenue opportunities US Drug Enforcement Administration to reclassify ca...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Where are we in terms of US legalisation of cannabis? What about the current legal landscape for cannabis in Australia? We look at the best performing ASX weed stocks this past month   Global weed stocks have been on bumpy ride over the p...

US Majority Leader Chuck Schumer is urging people to endorse SAFER Banking Act by signing petition Act aims to enhance access to traditional financial services for cannabis companies in the US Melodiol Global Health could benefit as one of...

Special Report: Melodiol Global’s subsidiary Mernova continues to gain traction in Canada as the company launches new cannabis products across various markets. Melodiol Global Health Limited (ASX:ME1)’s wholly-owned Canadian subsidiary, Mer...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

The ASX 200 erases early morning’s losses, rallying to close the day +0.3% higher.  This comes as the ABS released its monthly CPI report, which shows that YoY inflation was steady in February at 3.4% for a third straight month. The figure...

Melodiol Global Health reports total unaudited revenue of $3.1 million in first two months of FY24 Recreational cannabis subsidiary Mernova Medicinal contributes $1.45 million driven by Ritual branded products ME1 recently reported total...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ — TB Alliance’s new Peer-to-Peer Learning for Innovative Cu...

AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ — The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million...